In the current generation of ADCs, the linkers are more stable, and the cytotoxic agents are significantly more potent.
#Groove agent 4 cmc pd free#
In early ADCs, the linkers were too labile, which led to the release of free drug in the circulation and consequent off-target toxicity. ADC technology has vastly improved within the last several years. The antibody directs the cytotoxic agent to the tumor cell, thereby diminishing the side effect profile of the cytotoxic agent and enabling delivery of a more potent therapeutic because of the ability to control the target and the side effects. There are 4 components of ADC technology: the cancer, or target, antigen the antibody to that target the linker that connects the drug to the antibody and the drug itself. Head, Lymphoma Translational Research Laboratoryĭirector, Clinical Investigation and Translational ResearchĪbstract: Antibody-drug conjugates (ADCs) combine cytotoxic chemotherapy and antibody specificity. Clinical Advances in Hematology & Oncology Volume 10, Issue 8, Supplement 10 August 2012Ĭlinical Roundtable Monograph: Antibody-Drug Conjugate Technology Development for Hematologic Disordersīernard & Josephine Chaus Professor of Urologic Oncology
0 kommentar(er)
